NCT05891119 is a EARLY_PHASE1 clinical trial of Caffeine in Atopic Dermatitis, sponsored by Amgen.

Who is sponsoring NCT05891119?

NCT05891119 is sponsored by Amgen.

What drugs are being tested in NCT05891119?

Interventions in NCT05891119: Caffeine, Metoprolol, Midazolam, Warfarin, Vitamin K, Omeprazole, Rocatinlimab.

What condition does NCT05891119 study?

NCT05891119 studies Atopic Dermatitis.

Is NCT05891119 still recruiting?

NCT05891119 is currently completed. Last updated 23 December 2025.

Last reviewed 2025-12-23 · How we verify

NCT05891119

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

Completed EARLY_PHASE1 Last updated 23 December 2025

What this trial tests

EARLY_PHASE1 trial testing Caffeine in Atopic Dermatitis in 21 participants. Completed in 12 February 2025.

Timeline

3 June 2023

Primary endpoint
28 August 2024

12 February 2025

Quick facts

Lead sponsor	Amgen
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	21
Start date	3 June 2023
Primary completion	28 August 2024
Estimated completion	12 February 2025
Sites	7 locations across United States

Drugs / interventions tested

Caffeine (caffeine) — full drug profile →
Metoprolol (metoprolol) — full drug profile →
Midazolam (midazolam) — full drug profile →
Warfarin (warfarin) — full drug profile →
Vitamin K
Omeprazole (omeprazole) — full drug profile →
Rocatinlimab

Conditions studied

Atopic Dermatitis — all drugs for Atopic Dermatitis →

Sponsor

Amgen — full company profile →

Who can join

Adults 18 to 65, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of the study is to evaluate the pharmacokinetics (PK) of multiple cytochrome P450 (CYP450) substrates alone and in combination with rocatinlimab in participants with moderate to severe atopic dermatitis (AD).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Caffeine

Trials testing the same drug.

NCT07456670 — Caffeine for Infants Born at 28 to 34 Weeks Receiving Respiratory Support · Phase 2 · not yet recruiting
NCT07520864 — Effects of Caffeine on Elite Weightlifting Performance · NA · completed
NCT07479875 — Caffeine Supplementation and Strength Endurance in Brazilian Jiu-jitsu Athletes · NA · completed
NCT07466732 — Effects of Caffeine Ingestion on Morning Cognitive and Muscle Repeated Sprint Performance in Males · EARLY_PHASE1 · enrolling by invitation
NCT07458594 — Combined Caffeine and Rhodiola Rosea on Aerial Duel Performance in Soccer · NA · completed

Other recruiting trials for Atopic Dermatitis

Currently open trials in the same condition.

NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis · Phase 2 · recruiting
NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting

Other Amgen trials

Trials by the same sponsor.

NCT07223190 — A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Ly · Phase 3 · not yet recruiting
NCT07493512 — Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer · Phase 1 · not yet recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT06987539 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Gen · Phase 2 · recruiting
NCT05909761 — Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregn · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05891119 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amgen
Last refreshed: 23 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05891119.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing